Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Completed · Phase 2

Conditions studied: Acute Lymphoblastic Leukemia

In brief

The goal of this clinical research study is to learn if a special combination of chemotherapy drugs called "augmented hyper-CVAD chemotherapy" given over 6 to 8 months followed by monthly maintenance chemotherapy for one year can help to control acute lymphoblastic leukemia or lymphoblastic lymphoma. The safety of this therapy will also be studied.

Key facts

Study ID

NCT00890656

Run by

M.D. Anderson Cancer Center

People needed

90

Starts

2003-06-01

Expected to finish

2011-01-01

Last updated by the study team

2012-02-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously treated acute lymphoblastic leukemia (ALL) (including Burkitt's lymphoma) or lymphoblastic lymphoma in relapse or primary refractory;
• No age restrictions;
• Zubrod performance status </= 3;
• Adequate liver (bilirubin </= 3mg/dl unless considered due to tumor) and renal function (creatinine </= 3mg/dl unless considered due to tumor);
• Adequate cardiac function (New York Heart Association (NYHA) < III as assessed by history and physical examination)

You may not qualify if…

• Not Applicable

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.